New AI partnership aims to bring advanced monitoring solutions to Texas

A new partnership between care.ai and the Texas Hospital Association (THA) is focused on getting AI-powered autonomous monitoring technology implemented throughout the Lone Star State.

care.ai has already formed working relationships with healthcare providers throughout the United States, and this latest collaboration could get the company’s solutions—which provide real-time patient monitoring using advanced sensors—into hundreds of Texas hospitals.

“We’re incredibly proud to partner with THA to demonstrate AI’s powerful potential to revolutionize healthcare,” Chakri Toleti, founder and CEO of care.ai, said in a prepared statement. “As healthcare innovators, we are focused on bringing patients and providers closer together, making care more human. This partnership with THA will help bring that vision to life.”

“Texas hospitals have always been trailblazers when it comes to the use and adoption of leading-edge healthcare technology,” Fernando Martinez, PhD, president and CEO of the THA Foundation, said in the same statement. “Through this new partnership with care.ai, Texas hospitals will have the opportunity to experience the use of AI in a hands-on local lab environment. They will get to see in real time the value that autonomous monitoring can bring to their facilities. We’re proud to connect our members to cutting-edge technologies that have a transformative impact on healthcare delivery in Texas.”

In October 2019, care.ai announced collaborations with two technology juggernauts—Google and NVIDIA—to enhance its technology and make a bigger impact on patient care. 

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.